1. Home
  2. JCSE vs AKTX Comparison

JCSE vs AKTX Comparison

Compare JCSE & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JE Cleantech Holdings Limited

JCSE

JE Cleantech Holdings Limited

HOLD

Current Price

$1.28

Market Cap

6.5M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$13.43

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JCSE
AKTX
Founded
1999
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
6.5M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
JCSE
AKTX
Price
$1.28
$13.43
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
25.2K
1.5M
Earning Date
05-14-2026
05-14-2026
Dividend Yield
8.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$0.12
52 Week High
$2.50
$29.32

Technical Indicators

Market Signals
Indicator
JCSE
AKTX
Relative Strength Index (RSI) 54.26 58.49
Support Level $1.02 $0.69
Resistance Level $1.32 N/A
Average True Range (ATR) 0.11 3.99
MACD 0.01 1.12
Stochastic Oscillator 45.71 39.63

Price Performance

Historical Comparison
JCSE
AKTX

About JCSE JE Cleantech Holdings Limited

JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company has two operating segments namely sale of cleaning systems and other equipment and provision of centralized dishware washing and general cleaning services. Geographically, the company derives a majority of its revenue from Singapore.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: